VERAXA Biotech Appoints Chief Scientific Officer to Advance BiTAC® Technology into Clinical Development

VERAXA Biotech AG (NASDAQ: VRXA) has appointed Dr. Christoph Erkel as chief scientific officer, a move that underscores the company's commitment to advancing its proprietary BiTAC® technology and oncology pipeline. Dr. Erkel, an antibody therapeutics specialist, will oversee the progression of these innovative therapies toward clinical development.

The lead BiTAC-TCE program employs a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. This precision targeting could reduce off-tumor toxicity, a common challenge in cancer immunotherapy. Recent scientific advice from Germany's Paul-Ehrlich-Institute provided clarity on the program's non-clinical development strategy, and preclinical data presented at the AACR Annual Meeting demonstrated selective activity against cells expressing both target molecules.

Beyond BiTAC, VERAXA is developing bispecific antibody-drug conjugates (ADCs) and other engineered antibody therapies, positioning the company to pursue multiple approaches to next-generation cancer treatment. The dual focus on T cell engagers and ADCs reflects a broader industry trend toward combination therapies and tailored biologics.

The appointment of Dr. Erkel comes at a critical juncture as VERAXA prepares to enter clinical trials. His expertise in antibody therapeutics will be instrumental in navigating the complex regulatory and scientific landscape. The company's foundation on breakthroughs at the European Molecular Biology Laboratory (EMBL) lends additional scientific credibility.

For investors, this development signals potential for value creation if the BiTAC® platform proves successful in clinical testing. The oncology market remains highly competitive, but differentiated approaches like conditionally active T cell engagers could capture significant market share. VERAXA's progress will be closely watched, especially given the recent scientific validation from the Paul-Ehrlich-Institute.

To view the full article, visit https://ibn.fm/dSC1p. For regular updates about VERAXA Biotech, visit www.VERAXA.com. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.